Tübingen, Germany

Anke Weissenborn



Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2004-2010

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Anke Weissenborn

Introduction

Anke Weissenborn, a distinguished inventor based in Tübingen, Germany, has made significant strides in the field of biotechnology and molecular biology. With a total of four patents to her name, Weissenborn's work is renowned for advancing production processes related to essential amino acids and genetic sequencing.

Latest Patents

Her latest patents include a groundbreaking invention titled "Nucleotide sequence encoding the dapC gene and process for the production of L-lysine." This invention focuses on an isolated polynucleotide from coryneform bacteria that is instrumental in the production of L-lysine, a crucial amino acid used in various applications. Additionally, her research encompasses the identification of nucleotide sequences coding for the ACP gene, showcasing her innovative approach to genetic engineering.

Career Highlights

Anke Weissenborn has built her career with influential companies such as Degussa Aktiengesellschaft and Evonik Degussa GmbH. Her dedication and expertise in biotechnology have positioned her as a key player in developing advanced biotechnological methods and products.

Collaborations

Throughout her career, Weissenborn has collaborated with notable scientists, including Walter Pfefferle and Lothar Eggeling. These collaborations have enriched her research and led to significant advancements in the field, emphasizing the importance of teamwork and shared knowledge in scientific innovation.

Conclusion

Anke Weissenborn's contributions to biotechnology through her patents and collaborations remain vital to the industry. Her innovative work continues to influence research and applications, paving the way for future advancements in molecular biology and genetic engineering.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…